Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) traded down 3.8% during mid-day trading on Tuesday . The stock traded as low as $13.61 and last traded at $13.61. 1,520 shares were traded during trading, a decline of 98% from the average session volume of 69,687 shares. The stock had previously closed at $14.15.
Gyre Therapeutics Stock Down 0.6 %
The stock has a 50 day moving average price of $12.95 and a 200 day moving average price of $13.13.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $25.23 million for the quarter. On average, research analysts forecast that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.
Institutional Trading of Gyre Therapeutics
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- What is a Dividend King?
- WD-40 Company Gears Up for a Double-Digit Stock Advance
- How to Most Effectively Use the MarketBeat Earnings Screener
- Monster and Celsius Energized: Which Stock Offers More Upside?
- Where to Find Earnings Call Transcripts
- Sherwin-Williams Plunges Into Buying Opportunity: Time to Buy?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.